ESMO 2026: Day-Three Floor Digest Highlights Eight Trial Talking Points
Start here
On 27 October 2026, the third day of the ESMO congress, the floor digest tracked the trials drawing the most attention. DELLPHI-305, nivolumab and TROFUSE-005 led the conversation, followed by HER2-focused data, the VOLGA trial, KEYNOTE-C93 and ASTRIDE, with precision oncology a recurring theme across discussions. The digest ranks these by how heavily they featured in the day's corridor and session talk, giving readers a quick read on which late-breaking results are shaping sentiment at the meeting. Follow-up analyses of the underlying data for each trial are the natural next step for readers who want detail beyond the rankings.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- cba-usa.newsPickESMO 2026 · 27 Oct floor digest
1. DELLPHI-305 (4); 2. nivolumab (4); 3. TROFUSE-005 (4); 4. HER2 (3); 5. VOLGA (3); 6. KEYNOTE-C93 (3); 7. ASTRIDE (3); 8. #PRECISIONONCOLOGY (3)
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.